These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Cheng SH; Smith AE Gene Ther; 2003 Aug; 10(16):1275-81. PubMed ID: 12883523 [TBL] [Abstract][Full Text] [Related]
44. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Jeyakumar M; Butters TD; Dwek RA; Platt FM Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816 [TBL] [Abstract][Full Text] [Related]
45. Models to study basic and applied aspects of lysosomal storage disorders. Gaudioso Á; Silva TP; Ledesma MD Adv Drug Deliv Rev; 2022 Nov; 190():114532. PubMed ID: 36122863 [TBL] [Abstract][Full Text] [Related]
46. A Journey towards Understanding the Molecular Pathology and Developing Therapies for Lysosomal Storage Disorders. Tikkanen R Cells; 2021 Dec; 11(1):. PubMed ID: 35011597 [TBL] [Abstract][Full Text] [Related]
47. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders. Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793 [TBL] [Abstract][Full Text] [Related]
49. Advances in therapies for neurological lysosomal storage disorders. Ellison S; Parker H; Bigger B J Inherit Metab Dis; 2023 Sep; 46(5):874-905. PubMed ID: 37078180 [TBL] [Abstract][Full Text] [Related]
50. Disruption of morphogenic and growth pathways in lysosomal storage diseases. Corrêa T; Feltes BC; Giugliani R; Matte U WIREs Mech Dis; 2021 Sep; 13(5):e1521. PubMed ID: 34730292 [TBL] [Abstract][Full Text] [Related]
51. Invertebrate models of lysosomal storage disease: what have we learned so far? Hindle S; Hebbar S; Sweeney ST Invert Neurosci; 2011 Dec; 11(2):59-71. PubMed ID: 22038288 [TBL] [Abstract][Full Text] [Related]
52. Musculoskeletal manifestations of lysosomal storage disorders. Aldenhoven M; Sakkers RJ; Boelens J; de Koning TJ; Wulffraat NM Ann Rheum Dis; 2009 Nov; 68(11):1659-65. PubMed ID: 19822711 [TBL] [Abstract][Full Text] [Related]
53. From bedside to cell biology: a century of history on lysosomal dysfunction. Coutinho MF; Matos L; Alves S Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857 [TBL] [Abstract][Full Text] [Related]
54. Exploiting the Potential of Rigon L; De Filippis C; Napoli B; Tomanin R; Orso G Biomedicines; 2021 Mar; 9(3):. PubMed ID: 33800050 [TBL] [Abstract][Full Text] [Related]
55. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Hemsley KM; Hopwood JJ Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322 [TBL] [Abstract][Full Text] [Related]
56. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. Liu G; Martins I; Wemmie JA; Chiorini JA; Davidson BL J Neurosci; 2005 Oct; 25(41):9321-7. PubMed ID: 16221840 [TBL] [Abstract][Full Text] [Related]
57. Human iPSC-Based Models for the Development of Therapeutics Targeting Neurodegenerative Lysosomal Storage Diseases. Luciani M; Gritti A; Meneghini V Front Mol Biosci; 2020; 7():224. PubMed ID: 33062642 [TBL] [Abstract][Full Text] [Related]
58. Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities. Hoffmann B; Mayatepek E Neuropediatrics; 2005 Oct; 36(5):285-9. PubMed ID: 16217702 [TBL] [Abstract][Full Text] [Related]
59. Treatment perspectives for the lysosomal storage diseases. Grabowski GA Expert Opin Emerg Drugs; 2008 Mar; 13(1):197-211. PubMed ID: 18321157 [TBL] [Abstract][Full Text] [Related]